Targeted Oncology Staff

Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.

During a Targeted Oncology Case-Based Roundtable event, Jakub Svoboda, MD, discussed the case of a 75-year-old patient with diffuse large b-cell lymphoma.

Treatment of patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA clinical trial resulted in practice-changing disease-free survival with tolerable safety.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed the case of a 59-year-old patients with non–small cell lung cancer.

The FDA has granted the expanded use of ravulizumab-cwvz to include the treatment of children aged 1 month and older and adolescents with paroxysmal nocturnal hemoglobinuria.

During a Targeted Oncology Case-Based Roundtable event, Sikander Ailawadhi, MD, discussed maintenance therapy for patients with multiple myeloma.

Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.

David H. Vesole, MD, PhD, discussed triplet regimens used for the treatment of transplant ineligible multiple myeloma during a Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, discussed the treatment options available for patients with transplant-eligible multiple myeloma with a group of peers during a Targeted Oncology Case-Based Roundtable event.

Based on clinical trial research, ruxolitinib is a viable option for the treatment of acute graft-versus-host-disease. The agent has been shown to induce durable responses.

Matthew Smith, MD, PhD​, led a panel discussion around the various treatment options for a patient with nonmetastatic castration-resistant prostate cancer.

Joseph Mikhael, MD, explained the prognostic factors for consideration when treating newly-diagnosed multiple myeloma.

Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.

Treatment options are available for patients with late-stage gastric cancer in the early- to late-line settings.

Zanetta Lamar, MD, discussed the efficacy of tafasitamab in combination with lenalidomide in the clinical trial setting.

The most recent data on ruxolitinib support its continued use as frontline treatment of patients with myelofibrosis.

Eleni Efstathiou, MD, PhD, discussed clinical trials which support the use of certain treatment regimen for patients with nonmetastatic castration-resistant prostate cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Atish D. Choudhury, MD, PhD, discussed methods for treating patients with nonmetastatic prostate cancer with a group of peers.

Jaffer A. Ajani, MD led a discussion around biomarkers to consider when determining systemic therapy for patients with stage IV gastric adenocarcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Michael A. Carducci, MD, reviewed the results of the CARD trial to support his recommendation of cabazitaxel for the treatment of a 75-year-old man with metastatic castration-resistant prostate cancer.

The PROfound and TRITON2 clinical trials have demonstrated the benefit of the PARP inhibitors olaparib and rucaparib for the treatment of metastatic castration-resistant prostate cancer.

According to findings from a subgroup analysis of the TALAPRO-1 trial, men with heavily pretreated metastatic castration-resistant prostate cancer, with germline and/or homozygous tumor DNA damage response alterations are most likely to respond to talazoparib.

Helen Moon, MD, reviewed the data from the JAVELIN Bladder 100 trial, which support the use of avelumab as maintenance therapy for patients with metastatic bladder cancer.

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Tanya Dorff, MD, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Ticiana Leal, MD, discussed the case of a patient with non–small cell lung cancer with a group of peers.

Karen L. Reckamp, discussed the progression-free survival benefit achieved with ramucirumab in patients with EGFR-positive lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Matthew Smith, MD, PhD, discussed genomic testing in prostate cancer with a group of peers.

Ravi Salgia, MD, PhD, discussed the case of a 59-year-old patient with non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.